News Report | November 9, 2021
FDA Approves DreaMed Diabetes’ AI Clinical Decision Support For Type 2 Diabetes
On October 6, 2021, the U.S Food and Drug Administration (FDA) issued market clearance for the Advisor Pro Al Clinical Decision Support System care platform for diabetes by DreaMed Diabetes AI LTD. The new FDA clearance expands the platform’s target population to consumers with both type 1 and type 2 diabetes. The company describes the platform as a “digital endocrinologist” for use in primary care settings.
The system provides primary care professionals with insulin titration recommendations based on data collected by continuous glucose sensors and/or blood glucose meters. The data is uploaded to the Advisor Pro platform . . .